rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-421-425rsp-2754Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHВлияние терапии на качество жизни, связанное со здоровьем, у пациентов с системной красной волчанкой (по данным регистра РЕНЕССАНС)IMPACT OF THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (ACCORDING TO THE RENAISSANCE REGISTER)ВоробьеваЛ. Д.VorobyevaL. D.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

evagolland@gmail.comАсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СоловьевС. К.SolovyevS. K.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

КойлубаеваГ. М.KoilubaevaG. M.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040,  Kyrgyzstan

ГлуховаС. И.GlukhovaS. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНациональный центр кардиологии и терапии им. академика М. МиррахимоваКыргызстанAcademician M. Mirrakhimov National Center for Cardiology and TherapyKyrgyzstan201915092019574421425Copyright © Воробьева Л.Д., Асеева Е.А., Соловьев С.К., Койлубаева Г.М., Глухова С.И., 20192019Воробьева Л.Д., Асеева Е.А., Соловьев С.К., Койлубаева Г.М., Глухова С.И.Vorobyeva L.D., Aseeva E.A., Solovyev S.K., Koilubaeva G.M., Glukhova S.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2754

Цель исследования – оценка изменения качества жизни, связанного со здоровьем (КЖСЗ), у пациентовс системной красной волчанкой (СКВ) на фоне проводимой терапии.Материал и методы. В исследование включено 128 пациентов с достоверной СКВ, соответствующих критериям SLICC 2012 г. У 68 из них проводилась стандартная терапия, 60 получали генно-инженерные биологические препараты (ГИБП). Всем больным во время 1-го визита и через 12 мес проводилась оценка активности заболевания по индексу SLEDAI-2K и органных повреждений при помощи индекса повреждения SLICC (ИП). КЖСЗ оценивалась с помощью опросника LupusQoL, который пациенты заполняли самостоятельно.Результаты и обсуждение. Во время 1-го визита в группе, получающей стандартную терапию, индекс активности составлял в среднем 8,0±7,3, в группе ГИБП – 15,4±7,6 (p≤0,001), ИП – 1,2±0,9 и 1,8±1,8 (p=0,008) соответственно. КЖСЗ у пациентов, получающих ГИБП, было достоверно ниже по всем шкалам опросника, кроме шкалы, оценивающей зависимость от других людей, и шкалы «Эмоциональное здоровье». Через 12 мес, на момент 2-го визита, как в группе, получающей стандартную терапию, так и в группе ГИБП отмечается достоверное снижение активности. При оценке КЖСЗ в группе, находящейся на терапии ГИБП, через 12 мес отмечается достоверное улучшение по шкалам «Боль», «Планирование», «Интимные отношения», «Эмоциональное здоровье», «Образ тела» и «Усталость». В группе стандартной терапии статистически значимое улучшение наблюдалось по шкале «Зависимость от других людей». По всем остальным шкалам опросника также наблюдалась положительная динамика КЖСЗ, однако она не достигала статистической значимости.

Objective: to assess changes in health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) during performed therapy.Subjects and methods. The investigation included 128 patients with reliable SLE who fulfilled the 2012 SLICC criteria. Sixty-eight patients received standard therapy; 60 used biological agents (BA). During the first visit and at 12 months, all the patients were assessed for disease activity using by SLEDAI-2K and for organ damage employing the SLICC damage index (DI). HRQoL was assessed by the LupusQoL questionnaire that was filled out by the patients independently.Results and discussion. At Visit 1, the disease activity index averaged 8.0±7.3 in the standard therapy group and 15.4±7.6 in the BA group (p≤0.001); DI was 1.2±0.9 and 1.8±1.8, respectively (p=0.008). BA-treated patients had significantly lower HRQoL scores on all questionnaire scales, except «dependence on others» and «emotional health» ones Both the standard therapy and BA groups showed significantly lower disease activity during Visit 2 at 12 months. HRQoL assessment revealed significant improvements in the scales «pain», «planning», «intimate relationships», «emotional health», «body image», and «fatigue» in the BA group. The standard therapy group had a statistically significant improvement in the scale «dependence on others». All the other scales of the questionnaire displayed a positive change in HRQoL; however, it did not reach statistical significance.

системная красная волчанкакачество жизнисвязанное со здоровьемLupusQolsystemic lupus erythematosushealth-related quality of lifeLupusQolReferencesСоловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16 doi: 10.14412/1995-4484-2015-9-16Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the International Task Force and Russian experts’ commentaries. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.). doi: 10.14412/1995-4484-2015-9-16Fernandez-Nebro A, de la Fuente J, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMA B study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627Fernandez-Nebro A, de la Fuente J, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMA B study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627Gamble R, Dellavalle R. A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus. Arch Dermatol. 2012;148(3):376-8. doi: 10.1001/archdermatol.2011.1266Gamble R, Dellavalle R. A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus. Arch Dermatol. 2012;148(3):376-8. doi: 10.1001/archdermatol.2011.1266Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, et al. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281-96. doi: 10.1016/j.reuma.2013.04.001Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, et al. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281-96. doi: 10.1016/j.reuma.2013.04.001Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(10 suppl. 1). doi: 10.1177/0961203312465781Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(10 suppl. 1). doi: 10.1177/0961203312465781Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-9.Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-9.Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71. doi: 10.1093/rheumatology/ken479Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-9.Kumar K, Gordon C, Barry R, et al. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837-44. doi: 10.1177/0961203311398512Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71. doi: 10.1093/rheumatology/ken479Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9 doi: 10.14412/1995-4484-2018-302-309Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71. doi: 10.1093/rheumatology/ken479Furie R, Petri MA, Strand V, et al. Clinical, laboratory and health related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1:e000031. doi: 10.1136/lupus-2014-000031Kumar K, Gordon C, Barry R, et al. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837-44. doi: 10.1177/0961203311398512Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus. 2016;25:1111-21. doi: 10.1177/0961203316652494Kumar K, Gordon C, Barry R, et al. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837-44. doi: 10.1177/0961203311398512Новик АА, Ионова ТИ, Кайнд П. В кн.: Концепция исследования качества жизни в медицине. Санкт-Петербург: Элби; 1999. 140 с.Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309McElhone K, Abbott J, Teh L-S. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10). doi: 10.1177/0961203306071710Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309Furie R, Cash J, Cronin M, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257-65.Furie R, Petri MA, Strand V, et al. Clinical, laboratory and health related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1:e000031. doi: 10.1136/lupus-2014-000031Polderman M, Huizinga T, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112-5. doi: 10.1136/ard.60.2.112Furie R, Petri MA, Strand V, et al. Clinical, laboratory and health related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1:e000031. doi: 10.1136/lupus-2014-000031Dobkin PL, DaCosta D, Joseph L, et al. Counterbalancing patient demands with evidence: results from a pan-Canadian randomised clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002;24:88-99. doi: 10.1207/S15324796ABM2402_05Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus. 2016;25:1111-21. doi: 10.1177/0961203316652494Strand V, Aranow C, Cardiel M, et al. Improvement of healthrelated quality of life in SLE patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12:677-86. doi: 10.1191/0961203303lu440oaAnnapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus. 2016;25:1111-21. doi: 10.1177/0961203316652494Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279Novik AA, Ionova TI, Kaind P. In: Kontseptsiya issledovaniya kachestva zhizni v meditsine [The concept of the study of quality of life in medicine]. St. Petersburg: Elbi; 1999. 140 p. (In Russ.).Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosteroneNovik AA, Ionova TI, Kaind P. In: Kontseptsiya issledovaniya kachestva zhizni v meditsine [The concept of the study of quality of life in medicine]. St. Petersburg: Elbi; 1999. 140 p. (In Russ.).supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550McElhone K, Abbott J, Teh L-S. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10). doi: 10.1177/0961203306071710Schinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oaMcElhone K, Abbott J, Teh L-S. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10). doi: 10.1177/0961203306071710Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233Furie R, Cash J, Cronin M, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257-65.Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865Furie R, Cash J, Cronin M, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257-65.Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718Polderman M, Huizinga T, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112-5. doi: 10.1136/ard.60.2.112Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062Polderman M, Huizinga T, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112-5. doi: 10.1136/ard.60.2.112Tse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xxDobkin PL, DaCosta D, Joseph L, et al. Counterbalancing patient demands with evidence: results from a pan-Canadian randomised clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002;24:88-99. doi: 10.1207/S15324796ABM2402_05Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776Dobkin PL, DaCosta D, Joseph L, et al. Counterbalancing patient demands with evidence: results from a pan-Canadian randomised clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002;24:88-99. doi: 10.1207/S15324796ABM2402_05Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828Strand V, Aranow C, Cardiel M, et al. Improvement of healthrelated quality of life in SLE patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12:677-86. doi: 10.1191/0961203303lu440oaThumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.Strand V, Aranow C, Cardiel M, et al. Improvement of healthrelated quality of life in SLE patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12:677-86. doi: 10.1191/0961203303lu440oaRood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosteroneNordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosteroneNordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosteroneNordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosteronesupplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550Schinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oaSchinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oaSchinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oaSchinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oaMerrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062Tse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xxTse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xxTse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xxTse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xxGrootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.

The authors declare that there are no conflicts of interest present.